Literature DB >> 27302930

Unsafe Drugs Were Prescribed More Than One Hundred Million Times in the United States Before Being Recalled.

Sonali Saluja1, Steffie Woolhandler2, David U Himmelstein2, David Bor3, Danny McCormick3.   

Abstract

For some drugs, safety concerns are only discovered after they have been on the market, sometimes for several years. The U.S. Food and Drug Administration (FDA) has adopted several policies that could increase the likelihood of approving a potentially unsafe medication. We attempted to quantify the number of exposures in the United States to drugs that were newly approved but later withdrawn from the market. We obtained a list of all drugs approved and subsequently withdrawn from the U.S. market due to safety concerns between 1993 and 2010. Using a representative sample of outpatient physician office visits in the National Ambulatory Medical Care Survey, we estimated the number of visits in the United States at which these unsafe drugs were prescribed. Seventeen drugs were approved and later withdrawn during this 18-year period and were prescribed at 112 million physician office visits in the United States. Nine of these drugs were prescribed more than 1 million times before their market withdrawal. New drugs that are later withdrawn due to being unsafe are frequently prescribed in the United States. To minimize the negative health consequences of prescribing potentially unsafe medications, we should reconsider some of the FDA policies that encourage the rapid approval and dissemination of new drugs. © Australian Council for Educational Research 2016.

Entities:  

Keywords:  United States food and drug administration; drug industry; pharmacoepidemiology; safety-based drug withdrawals

Mesh:

Year:  2016        PMID: 27302930     DOI: 10.1177/0020731416654662

Source DB:  PubMed          Journal:  Int J Health Serv        ISSN: 0020-7314            Impact factor:   1.663


  3 in total

Review 1.  Are Corporations Re-Defining Illness and Health? The Diabetes Epidemic, Goal Numbers, and Blockbuster Drugs.

Authors:  Linda M Hunt; Elisabeth A Arndt; Hannah S Bell; Heather A Howard
Journal:  J Bioeth Inq       Date:  2021-09-06       Impact factor: 2.216

2.  Initiation of new psychotropic prescriptions without a psychiatric diagnosis among US adults: Rates, correlates, and national trends from 2006 to 2015.

Authors:  Taeho Greg Rhee; Robert A Rosenheck
Journal:  Health Serv Res       Date:  2018-10-17       Impact factor: 3.402

3.  The discordance between evidence and health policy in the United States: the science of translational research and the critical role of diverse stakeholders.

Authors:  Mohsen Malekinejad; Hacsi Horvath; Harry Snyder; Claire D Brindis
Journal:  Health Res Policy Syst       Date:  2018-08-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.